vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Skyward Specialty Insurance Group, Inc. (SKWD). Click either name above to swap in a different company.
Skyward Specialty Insurance Group, Inc. is the larger business by last-quarter revenue ($475.9M vs $281.3M, roughly 1.7× Guardant Health, Inc.). Skyward Specialty Insurance Group, Inc. runs the higher net margin — 10.5% vs -45.7%, a 56.1% gap on every dollar of revenue. On growth, Skyward Specialty Insurance Group, Inc. posted the faster year-over-year revenue change (44.8% vs 39.4%). Over the past eight quarters, Skyward Specialty Insurance Group, Inc.'s revenue compounded faster (30.4% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.
GH vs SKWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $475.9M |
| Net Profit | $-128.5M | $49.7M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 14.9% |
| Net Margin | -45.7% | 10.5% |
| Revenue YoY | 39.4% | 44.8% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $1.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $475.9M | ||
| Q4 25 | $281.3M | $385.6M | ||
| Q3 25 | $265.2M | $382.5M | ||
| Q2 25 | $232.1M | $319.9M | ||
| Q1 25 | $203.5M | $328.5M | ||
| Q4 24 | $201.8M | $304.4M | ||
| Q3 24 | $191.5M | $300.9M | ||
| Q2 24 | $177.2M | $279.9M |
| Q1 26 | — | $49.7M | ||
| Q4 25 | $-128.5M | $43.2M | ||
| Q3 25 | $-92.7M | $45.9M | ||
| Q2 25 | $-99.9M | $38.8M | ||
| Q1 25 | $-95.2M | $42.1M | ||
| Q4 24 | $-111.0M | $14.4M | ||
| Q3 24 | $-107.8M | $36.7M | ||
| Q2 24 | $-102.6M | $31.0M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 14.9% | ||
| Q4 25 | -43.0% | 14.2% | ||
| Q3 25 | -37.3% | 15.8% | ||
| Q2 25 | -45.9% | 15.6% | ||
| Q1 25 | -54.6% | 15.7% | ||
| Q4 24 | -62.4% | 6.1% | ||
| Q3 24 | -61.3% | 15.6% | ||
| Q2 24 | -56.8% | 14.4% |
| Q1 26 | — | 10.5% | ||
| Q4 25 | -45.7% | 11.2% | ||
| Q3 25 | -35.0% | 12.0% | ||
| Q2 25 | -43.0% | 12.1% | ||
| Q1 25 | -46.8% | 12.8% | ||
| Q4 24 | -55.0% | 4.7% | ||
| Q3 24 | -56.3% | 12.2% | ||
| Q2 24 | -57.9% | 11.1% |
| Q1 26 | — | $1.09 | ||
| Q4 25 | $-1.01 | $1.03 | ||
| Q3 25 | $-0.74 | $1.10 | ||
| Q2 25 | $-0.80 | $0.93 | ||
| Q1 25 | $-0.77 | $1.01 | ||
| Q4 24 | $-0.90 | $0.33 | ||
| Q3 24 | $-0.88 | $0.89 | ||
| Q2 24 | $-0.84 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $4.1M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.2B |
| Total Assets | $2.0B | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.1M | ||
| Q4 25 | $378.2M | $168.5M | ||
| Q3 25 | $580.0M | $160.1M | ||
| Q2 25 | $629.1M | $136.6M | ||
| Q1 25 | $698.6M | $112.9M | ||
| Q4 24 | $525.5M | $121.6M | ||
| Q3 24 | $585.0M | $105.6M | ||
| Q2 24 | $933.7M | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-99.3M | $1.0B | ||
| Q3 25 | $-354.5M | $961.4M | ||
| Q2 25 | $-305.5M | $899.9M | ||
| Q1 25 | $-250.8M | $850.7M | ||
| Q4 24 | $-139.6M | $794.0M | ||
| Q3 24 | $-60.1M | $797.5M | ||
| Q2 24 | $-1.6M | $723.6M |
| Q1 26 | — | $6.5B | ||
| Q4 25 | $2.0B | $4.8B | ||
| Q3 25 | $1.3B | $4.6B | ||
| Q2 25 | $1.3B | $4.3B | ||
| Q1 25 | $1.3B | $4.0B | ||
| Q4 24 | $1.5B | $3.7B | ||
| Q3 24 | $1.5B | $3.6B | ||
| Q2 24 | $1.6B | $3.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $408.1M | ||
| Q3 25 | $-35.4M | $171.4M | ||
| Q2 25 | $-60.3M | $88.2M | ||
| Q1 25 | $-62.7M | $96.8M | ||
| Q4 24 | $-64.5M | $305.1M | ||
| Q3 24 | $-51.1M | $168.0M | ||
| Q2 24 | $-94.0M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $402.6M | ||
| Q3 25 | $-45.8M | $168.9M | ||
| Q2 25 | $-65.9M | $87.1M | ||
| Q1 25 | $-67.1M | $96.6M | ||
| Q4 24 | $-83.4M | $300.9M | ||
| Q3 24 | $-55.3M | $167.6M | ||
| Q2 24 | $-99.1M | $18.4M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 104.4% | ||
| Q3 25 | -17.3% | 44.2% | ||
| Q2 25 | -28.4% | 27.2% | ||
| Q1 25 | -33.0% | 29.4% | ||
| Q4 24 | -41.3% | 98.8% | ||
| Q3 24 | -28.9% | 55.7% | ||
| Q2 24 | -55.9% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 1.4% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 2.4% | 0.3% | ||
| Q1 25 | 2.2% | 0.1% | ||
| Q4 24 | 9.4% | 1.4% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.44× | ||
| Q3 25 | — | 3.73× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 21.18× | ||
| Q3 24 | — | 4.58× | ||
| Q2 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
SKWD
Segment breakdown not available.
